Brian Burnette, MD
Hematology & Oncology · Green Bay, WINPI 1952523680
Payments from drug & device makers
What this record shows
This record is dominated by education: $67 of the $91 with a category attached, or 73.3%. 4 manufacturers reported payments, led by Acrotech Biopharma Inc. at 30.6% of the total. That places this record below the midpoint for hematology & oncology clinicians in WI, where the typical reported total is $411.
Across 5 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acrotech Biopharma Inc.$28
- Daiichi Sankyo Inc.$27
- Incyte Corporation$24
- Gilead$12
Across 27 payments — averaging $7278.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$97K
- Takeda Pharmaceuticals U.S.A., Inc.$70K
- E.r. Squibb & Sons, L.L.C.$23K
- National Marrow Donor Program$7K
- Merck$42
What the payments were for
- Food & beverage$2427%
- Education$6773%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acrotech Biopharma Inc. | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Incyte Corporation | 1 | $24 |
| Gilead | 1 | $12 |
How this compares
$91 in reported general payments places this provider in the 25th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 23 | $443,526 |
| CalquenceAcalabrutinib Maleate | 13 | $203,750 |
| Lenalidomide | 13 | $184,159 |
| ImbruvicaIbrutinib | 13 | $175,091 |
| Abiraterone Acetate | 81 | $63,624 |
| EliquisApixaban | 54 | $40,476 |
| Tamoxifen Citrate | 65 | $1,847 |
| Fentanyl | 19 | $1,784 |
| Ondansetron Hcl | 113 | $1,564 |
| Morphine Sulfate | 35 | $1,356 |
| Dexamethasone | 68 | $1,241 |
| Acyclovir | 53 | $1,133 |
| Morphine Sulfate ErMorphine Sulfate | 21 | $954 |
| Olanzapine | 56 | $776 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $583 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Green Bay
- Bradley HeralyGreen Bay$9K
- Matthew RyanGreen Bay$7K
- Parameswaran HariMilwaukee$1.3M
- Sayed Mehdi HamadaniMilwaukee$546K
- Binod DhakalMilwaukee$535K
- Deepak KilariMilwaukee$359K
- Ehab AtallahMilwaukee$344K
- Nirav ShahMilwaukee$207K
- Razelle KurzrockMilwaukee$199K
- Syed AbutalibMilwaukee$154K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.